Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda’s Diabetes Drug Found At Increased Risk Of Bone Fractures

This article was originally published in PharmAsia News

Executive Summary

Takeda Phamaceuticals' diabetes drug Actos (pioglitazone) has come under fire along with another major drug for being linked to a higher risk of bone fractures. A review of medical data has shown Takeda's drug and GlaxoSmithKline's Avandia (rosiglitazone), also for diabetes, may increase the risk by 43 percent. Although Avandia already had been linked to fractures, the new study showed patients taking Actos were equally at risk of broken bones. Both drugs are in the TZD drug class and together they have about four million customers in the U.S. The study was conducted by Medco Health Solutions and the University Of Texas. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts